New molecular tools for precision medicine in pituitary neuroendocrine tumors

被引:0
作者
Marques-Pamies, Montserrat [1 ]
Gil, Joan [2 ,3 ,4 ]
Valassi, Elena [3 ,5 ]
Pons, Laura [6 ]
Carrato, Cristina [6 ]
Jorda, Mireia [2 ]
Puig-Domingo, Manel [2 ,3 ,5 ,7 ,8 ]
机构
[1] Hosp Municipal Badalona, Dept Endocrinol, Badalona, Catalonia, Spain
[2] Germans Trias i Pujol Res Inst IGTP, Endocrine Res Unit, Badalona, Spain
[3] Hlth Inst Carlos III, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
[4] St Pau Hosp, Res Ctr Pituitary Dis, Dept Endocrinol, Barcelona, Spain
[5] Germans Trias i Pujol Univ Hosp, Dept Endocrinol & Nutr, Badalona, Spain
[6] Germans Trias i Pujol Hosp, Dept Pathol, Badalona, Spain
[7] Autonomous Univ Barcelona, Dept Med, Barcelona, Spain
[8] Germans Trias i Pujol Inst IGTP, Dept Endocrinol & Nutr, Cami Escoles S-N, Badalona 08916, Spain
来源
MINERVA ENDOCRINOLOGY | 2023年 / 49卷 / 03期
关键词
Pituitary neoplasms; Precision medicine; Systems biology; Multiomics; Biomarkers; SOMATOSTATIN ANALOGS; DNA METHYLATION; T2-WEIGHTED MRI; EXPRESSION; GENE; ADENOMAS; HORMONE; GROWTH; CABERGOLINE; PROLACTINOMAS;
D O I
10.23736/S2724-6507.23.04063-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Precision, personalized, or individualized medicine in pituitary neuroendocrine tumors (PitNETs) has become a major topic in the last few years. It is based on the use of biomarkers that predictively segregate patients and give answers to clinically relevant questions that help us in the individualization of their management. It allows us to make early diagnosis, predict response to medical treatments, predict surgical outcomes and investigate new targets for therapeutic molecules. So far, substantial progress has been made in this field, although there are still not enough precise tools that can be implemented in clinical practice. One of the main reasons is the excess overlap among clustered patients, with an error probability that is not currently acceptable for clinical practice. This overlap is due to the high heterogeneity of PitNETs, which is too complex to be overcome by the classical biomarker investigation approach. A systems biology approach based on artificial intelligence techniques seems to be able to give answers to each patient individually by building mathematical models through the interaction of multiple factors, including those of omics sciences. Integrated studies of different molecular omics techniques, as well as radiomics and clinical data are necessary to understand the whole system and to finally achieve the key to obtain precise biomarkers and implement personalized medicine. In this review we have focused on describing the current advances in the area of PitNETs based on the omics sciences, that are clearly going to be the new tool for precision medicine. (Cite this article as: Marques-Pamies M, Gil J, Valassi E, Pons L, Carrato C, Jorda M, et al. New molecular tools for precision medicine in pituitary neuroendocrine tumors. Minerva Endocrinol 2024 Jan 23. DOI: 10.23736/ S2724-6507.23.04063-0)
引用
收藏
页码:300 / 320
页数:21
相关论文
共 136 条
  • [1] [Anonymous], 2018, ord, V19, P179
  • [2] A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors
    Asa, Sylvia L.
    DiGiovanni, Rebecca
    Jiang, Jing
    Ward, Megan L.
    Loesch, Kimberly
    Yamada, Shozo
    Sano, Toshiaki
    Yoshimoto, Katsuhiko
    Frank, Stuart J.
    Ezzat, Shereen
    [J]. CANCER RESEARCH, 2007, 67 (15) : 7505 - 7511
  • [3] Role of KCNAB2 expression in modulating hormone secretion in somatotroph pituitary adenoma
    Ashton, Charles
    Rhie, Suhn K.
    Carmichael, John D.
    Zada, Gabriel
    [J]. JOURNAL OF NEUROSURGERY, 2021, 134 (03) : 787 - 793
  • [4] Pituitary adenomas evade apoptosis via noxa deregulation in Cushing's disease
    Asuzu, David T.
    Alvarez, Reinier
    Fletcher, Patrick A.
    Mandal, Debjani
    Johnson, Kory
    Wu, Weiwei
    Elkahloun, Abdel
    Clavijo, Paul
    Allen, Clint
    Maric, Dragan
    Ray-Chaudhury, Abhik
    Rajan, Sharika
    Abdullaev, Zied
    Nwokoye, Diana
    Aldape, Kenneth
    Nieman, Lynnette K.
    Stratakis, Constantine
    Stojilkovic, Stanko S.
    Chittiboina, Prashant
    [J]. CELL REPORTS, 2022, 40 (08):
  • [5] Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies
    Aydin, Busra
    Caliskan, Aysegul
    Arga, Kazim Yalcin
    [J]. EPMA JOURNAL, 2021, 12 (03) : 383 - 401
  • [6] Regulation of chromatin by histone modifications
    Bannister, Andrew J.
    Kouzarides, Tony
    [J]. CELL RESEARCH, 2011, 21 (03) : 381 - 395
  • [7] Update on the Genetics of Pituitary Tumors
    Barry, Sayka
    Korbonits, Marta
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2020, 49 (03) : 433 - +
  • [8] The Role of Long Noncoding RNAs in the Biology of Pituitary Adenomas
    Beylerli, Ozal
    Gareev, Ilgiz
    Pavlov, Valentin
    Chen, Xin
    Zhao, Shiguang
    [J]. WORLD NEUROSURGERY, 2020, 137 : 252 - 256
  • [9] Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain
    Biagetti, Betina
    Iglesias, Pedro
    Villar-Taibo, Rocio
    Moure, Maria-Dolores
    Paja, Miguel
    Araujo-Castro, Marta
    Ares, Jessica
    Alvarez-Escola, Cristina
    Vicente, Almudena
    Alvarez Guivernau, Elia
    Novoa-Testa, Iria
    Guerrero Perez, Fernando
    Camara, Rosa
    Lecumberri, Beatriz
    Garcia Gomez, Carlos
    Bernabeu, Ignacio
    Manjon, Laura
    Gaztambide, Sonia
    Cordido, Fernando
    Webb, Susan M.
    Luis Menendez-Torre, Edelmiro
    Diez, Juan J.
    Simo, Rafael
    Puig-Domingo, Manel
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [10] Perceptions of epigenetics
    Bird, Adrian
    [J]. NATURE, 2007, 447 (7143) : 396 - 398